Last reviewed · How we verify
NCT04557332
mHealth for ART Adherence by HIV+ African Americans
Phase 2 trial testing On the Dot Mobile app in HIV-1-infection in 109 participants. Completed in 30 May 2020.
30 May 2020
Quick facts
| Lead sponsor | Environment and Health Group, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 109 |
| Start date | 1 April 2019 |
| Primary completion | 30 May 2020 |
| Estimated completion | 30 May 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- On the Dot Mobile app
Conditions studied
- HIV-1-infection — all drugs for HIV-1-infection →
Sponsor
Environment and Health Group, Inc.
Who can join
30 and older, any sex, with HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this grant is to create and test a mobile app to support ART adherence among HIV+ African American adults.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04557332
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV-1-infection
Currently open trials in the same condition.
- NCT07293559 — Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States · recruiting
- NCT06919016 — A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1- · Phase 1 · active not recruiting
- NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV · Phase 2 · recruiting
- NCT06774872 — Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Succes · Phase 2 · recruiting
- NCT06890988 — Ending the Epidemic Interventions in the Dental Setting - UH3 · NA · recruiting
Other Environment and Health Group, Inc. trials
Trials by the same sponsor.
- NCT05009004 — Digital Health for Medication Adherence Among African Americans With Hypertension · NA · completed
- NCT04633200 — Mhealth for PrEP Adherence by Young Adult MSM, Phase 2 · NA · completed
- NCT05489172 — Mobile Health App to Reduce Diabetes in Latina Women With Prior Gestational Diabetes II · NA · completed
- NCT04233931 — Mhealth for Pre-exposure Prophylaxis Adherence by Young Adult MSM · NA · completed
- NCT03308032 — Self-Directed Online Training for Chinese Caregivers · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04557332 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Environment and Health Group, Inc.
- Last refreshed: 21 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04557332.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing